ACRV – acrivon therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares [Yahoo! Finance]
Acrivon Therapeutics (NASDAQ:ACRV) was downgraded by analysts at Wall St
Acrivon Therapeutics (NASDAQ:ACRV) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Form 4 Acrivon Therapeutics, For: Jan 17 Filed by: Miller Mary
Form 4 Acrivon Therapeutics, For: Jan 14 Filed by: Blume-Jensen Peter
Form 4 Acrivon Therapeutics, For: Jan 14 Filed by: Levy Adam D.
Form 4 Acrivon Therapeutics, For: Jan 13 Filed by: Devroe Eric
Form 8-K Acrivon Therapeutics, For: Jan 08
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.